Hamostat Injection (Aminocaproic Acid) | Used for Blood Clot Stabilization and Bleeding Control
Hamostat Injection contains Aminocaproic Acid, an antifibrinolytic medication used to control excessive bleeding by stabilizing blood clots. It is commonly administered during surgeries or in patients with bleeding disorders to prevent or reduce blood loss.
Product Overview
Hamostat Injection is a potent, sterile antifibrinolytic agent formulated to treat and manage critical bleeding episodes associated with excessive fibrinolysis (the breakdown of blood clots). Containing the active therapeutic compound Aminocaproic Acid, this intravenous intervention works by inhibiting the enzymes that dissolve blood clots, thereby stabilizing clot formation and promoting effective hemostasis (stopping bleeding). Hamostat Injection is primarily utilized in acute clinical settings—such as open-heart surgery, organ transplants, and severe trauma—where precise control over systemic or localized hyperfibrinolysis is vital to prevent severe blood loss and enhance patient recovery.
Product Composition
- Active Pharmaceutical Ingredient: Aminocaproic Acid (250mg / mL concentration strength)
- Dosage Form: Clear, colorless, sterile solution intended for intravenous infusion after appropriate dilution
- Core Excipients: Formulated with Water for Injection, with hydrochloric acid or sodium hydroxide utilized strictly for pH adjustment to maintain stability
Product Specification
| Product Parameter | Details |
| Brand Name | Hamostat Injection |
| Active Ingredient | Aminocaproic Acid |
| Therapeutic Class | Antifibrinolytics / Hemostatics |
| Available Strength | 250mg / mL (Available in 20 mL vials containing 5g of total active drug) |
| Primary Indication | Excessive bleeding resulting from systemic or localized hyperfibrinolysis |
Mechanism of Action
- Reversible Plasminogen Inhibition: Aminocaproic acid acts as a synthetic analog of the amino acid lysine, binding reversibly to the lysine-binding sites of plasminogen molecules.
- Blocking Activator Binding: This targeted binding blocks plasminogen activators from converting plasminogen into its active form, plasmin.
- Preventing Clot Degradation: By preventing the formation of plasmin and reducing its residual proteolytic activity, the drug stops the premature degradation of fibrin matrices. This directly stabilizes the structural integrity of natural blood clots and controls severe bleeding.
Key Benefits
- Demonstrates remarkable clinical efficacy in rapidly controlling heavy blood loss caused by hyperfibrinolysis during major surgical operations.
- Significantly decreases the overall requirement for post-operative blood transfusions, minimizing associated transfusion risks.
- Provides predictable, rapid systemic action when delivered via controlled intravenous infusion in emergency or intensive care settings.
- Serves as a critical therapeutic option for managing bleeding tendencies in patients undergoing complex cardiac surgeries or dental procedures with bleeding disorders.
Precautions
Important Precautions for Hamostat Injection (Aminocaproic Acid)
Hamostat Injection is used to control excessive bleeding and stabilize blood clots. Careful monitoring is important during treatment.
| Precaution Area | Details |
|---|---|
| Blood Clot Risk | Use carefully in clotting disorders. |
| Kidney Function | Monitor kidney health during use. |
| Heart Health | Use caution in heart disease. |
| Pregnancy | Use only if clearly needed. |
| Allergic Reaction | Avoid if allergic to ingredients. |
| Blood in Urine | Use carefully in urinary tract bleeding. |
| Monitoring | Regular blood tests may be required. |
Important Safety Advice
- Use only under medical supervision
- Report chest pain or swelling immediately
- Stay hydrated during treatment if advised
- Follow recommended dose and schedule
- Inform about any clotting disorder history
When to Avoid Hamostat Injection
- Active blood clotting disorders
- Severe kidney impairment without monitoring
- Known allergy to Aminocaproic Acid
- Unexplained blood clots history
Monitoring Requirements
- Kidney function tests
- Blood clotting assessments
- Observation for unusual swelling or pain
- Regular clinical monitoring during treatment
Usage
This potent antifibrinolytic agent must be administered exclusively in a clinical environment under direct medical supervision. Because rapid delivery can trigger profound cardiovascular changes, the infusion rate must be precisely regulated using an automated electronic pump. Healthcare professionals must frequently assess the patient’s coagulation profiles, check for signs of muscular toxicity, and perform continuous vital sign checks to ensure safety throughout the treatment course.
| Parameter | Clinical Guidelines |
| Intravenous Dosage | Treatment typically begins with an initial loading dose of 4g to 5g infused over the first hour, followed by a continuous infusion of 1g per hour. |
| Administration Route | Intravenous infusion only. The concentrated solution must be appropriately diluted with compatible IV fluids, such as 0.9% Normal Saline or 5% Dextrose, before use. |
| Infusion Velocity | Avoid rapid intravenous bolus injections. Infuse the drug slowly to minimize the acute risk of sudden low blood pressure (hypotension) or irregular heartbeats. |
| Patient Monitoring | Closely track fluid output and monitor for signs of skeletal muscle breakdown (myopathy), especially during prolonged or high-dose therapy courses. |
Uses
Management of Surgical Hyperfibrinolysis: Indicated to prevent and treat severe, life-threatening blood loss during complex cardiac procedures, liver transplants, and extensive orthopedic operations.
Control of Post-Operative Bleeding: Prescribed to manage acute, excessive hemorrhaging following prostatectomies or specialized cardiothoracic procedures where natural blood clots dissolve prematurely.
Therapy for Hematological Disorders: Utilized as a supportive treatment to control severe mucosal or internal bleeding in patients suffering from acute leukemia, severe aplastic anemia, or profound thrombocytopenia.
Prophylaxis in Bleeding Diatheses: Employed to prevent heavy, prolonged bleeding during dental or minor surgical procedures in patients with inherited clotting disorders like hemophilia.
Side Effects
Possible Side Effects of Hamostat Injection (Aminocaproic Acid)
Hamostat Injection may cause some side effects during bleeding management treatment. Many effects are mild, but some may require close attention.
| Side Effect Type | Details |
|---|---|
| Common Effects | Nausea, vomiting, headache. |
| Blood Pressure | Low blood pressure may occur. |
| Muscle Effects | Muscle weakness or pain. |
| Skin Reactions | Rash or itching. |
| Clotting Effects | Increased risk of blood clots. |
| Injection Site | Pain or irritation at site. |
Common Side Effects
- Nausea
- Vomiting
- Headache
- Mild dizziness
Less Common But Important Effects
- Muscle pain or weakness
- Skin rash or itching
- Low blood pressure
- Increased blood clot risk
When to Be Careful
- Chest pain or breathing difficulty
- Swelling in legs or sudden pain
- Severe allergic reactions
- Unusual muscle weakness
General Note
- Most side effects are manageable with monitoring
- Report any unusual symptoms early
- Seek medical attention for severe reactions
FAQs
Q: What is Hamostat Injection used for?
A: This antifibrinolytic medication is used in acute clinical settings to treat and prevent severe bleeding episodes. It is indicated when bleeding is caused by hyperfibrinolysis, a condition where the body breaks down blood clots too quickly.
Q: How does Aminocaproic Acid stop excessive bleeding?
A: It acts as a synthetic block that binds reversibly to plasminogen. By doing this, it prevents plasminogen from turning into plasmin—the enzyme responsible for dissolving blood clots—thereby stabilizing natural fibrin clots so the body can stop bleeding.
Q: How is this medication given to a patient?
A: It must be administered strictly via intravenous infusion. It is typically given as a rapid initial loading dose followed by a continuous, slow infusion over several hours, handled entirely by trained healthcare professionals.
Q: Can Hamostat Injection cause blood clots to form where they shouldn't?
A: Yes, because this drug prevents clots from dissolving, it carries a risk of causing abnormal clotting. It must be used with extreme caution in patients with a history of thromboembolic disease, such as deep vein thrombosis or pulmonary embolism.
Q: What rapid infusion risks should medical staff monitor?
A: Infusing this medication too quickly can cause sudden, severe hypotension (low blood pressure), bradycardia (slow heart rate), or abnormal heart rhythms. The infusion rate must be carefully controlled using an electronic pump.
Q: What are the common side effects of this medication?
A: Patients may experience dizziness, headache, nausea, diarrhea, nasal congestion, or localized injection site irritation. A more serious but less common side effect is myopathy, which causes muscle weakness and damage.
Interactions
Drug Interactions of Hamostat Injection (Aminocaproic Acid)
Hamostat Injection may interact with medicines that affect blood clotting or bleeding control. Careful monitoring is important during combined therapy.
| Medicine or Product Type | Interaction Details |
|---|---|
| Blood Thinners | May reduce treatment effectiveness. |
| Clotting Medicines | Can increase clot formation risk. |
| Hormonal Medicines | May raise blood clot risk. |
| Factor Concentrates | Can increase clotting effects. |
| Antifibrinolytic Drugs | May increase side effect risk. |
| Herbal Supplements | Some may affect bleeding risk. |
Important Interaction Advice
- Inform about all blood clotting or bleeding medicines
- Avoid combining clot affecting medicines without guidance
- Monitor closely for swelling or unusual pain
- Do not start or stop medicines without advice
General Guidance
- Regular blood monitoring may be needed
- Watch for signs of abnormal clotting
- Report unusual bleeding or bruising
- Maintain follow-up during treatment
Additional Note
- Share complete medication history before starting Hamostat Injection to reduce interaction risks
| Manufacturer | : | Samarth Pharma, India |
| Trade Name | : | Amicar |
| Generic Search | : | Aminocaproic Acid |
| Strength | : | 25mg |
Latest Products
